Reports Q1 revenue $186.6M, consensus $180.26M. Reports Total End of Period Subscribers of 3.4 million, including 135 thousand End of Period Clinical Subscribers, with Subscription Revenues Per Paid Weeks up 4.8% vs. prior year period. “We are making progress on our strategic priorities with continued momentum in our Clinical business, while laying the foundation for long-term, sustainable growth,” said Tara Comonte, President and CEO. “As the weight management landscape evolves, we believe our unique combination of science-backed behavioral support, clinical care, and engaged community positions us to deliver superior outcomes. As we navigate this period of significant reset, we remain focused on our key priorities: delivering a unified and engaging member experience, revitalizing our brand, innovating and expanding adjacent revenue streams, and driving operational excellence and efficiency throughout the organization. As we execute our strategy with discipline, we are confident in our ability to stabilize the business and build the path back to growth, continuing our six-decade legacy of helping millions achieve healthier lives.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WW:
- Weight Watchers options imply 36.2% move in share price post-earnings
- Unusually active option classes on open May 5th
- Weight Watchers options imply 45.5% move in share price post-earnings
- 3 Penny Stocks to Watch Now, 5/1/25
- WW International Stock (WW) Doubles on Eli Lilly Weight-Loss Drug Partnership